NCT04099043已完成不适用
Cascade Continuous Glucose Monitor 15-day Performance Assessment
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- 15-day Continuous Glucose Monitoring
研究概览
简要总结
To validate the feasibility of a 15-day wear period of the Cascade CGM system
详细描述
To assess a 15-day wear period for the Cascade CGM. This study includes ten subjects who will interface with the system and take finger stick BGM glucose values for calibration. The wear period includes four in-clinic days frequent blood draws and eleven at home days at a single testing site.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •• Signed informed consent form
- •Diagnosis of type 1 or type 2 (on insulin therapy) diabetes mellitus for at least 6 months
- •18 years of age or older
- •Currently self-monitoring capillary blood glucose (on average at least three times per day or more) or on a CGM for at least three months
- •Willing to have blood glucose levels manipulated into high and low glucose levels during in clinic days if deemed appropriate per the protocol based on insulin use.
- •Willing to follow all study procedures, including attending all clinic visits during which a venous line will be inserted for blood sampling, wearing CGM sensors for entire study, performing fingertip glucose tests for self-monitoring and calibration, and keeping a diary of activities.
- •Be willing to wear two investigational CGM devices.
排除标准
- •• Known allergy to medical grade adhesives
- •Magnetic Resonance Imaging (MRI) scheduled during CGM sensor wear period
- •Persons with type 2 diabetes using diet and exercise only for diabetes management
- •Used an investigational drug within 30 days prior to study entry
- •Hematocrit < 32% (obtained during screening)
- •Inadequate veins (in the opinion of the investigator) or known contraindication to placement of a dedicated peripheral line for venous blood withdrawal
- •Symptomatic coronary artery disease with a history of angina, or history of a myocardial infarction or coronary intervention (e.g., percutaneous transluminal coronary angioplasty [PTCA], stent placement), or coronary artery bypass graft (CABG) within the past six months
- •Diagnosis of the following diabetic autonomic neuropathies: orthostatic hypotension, heart rate anomalies, gastroparesis
- •Cerebrovascular incident within the past six month
- •History or presence of eczema, psoriasis, atopic or contact dermatitis
- •Subject is pregnant at the start of the study.
- •Current use or within one-week exposure to topical medications at the proposed insertion sites
- •Seizure disorder (epilepsy)
- •Malignancy within the past five years, except basal cell or squamous cell skin cancers
- •Major surgical operation within 30 days prior to screening
- •Other medical conditions that would pose safety concerns, interfere with study conduct or seriously compromise study integrity (reason for exclusion will be clearly documented by investigator or designee)
结局指标
主要结局
15-day Continuous Glucose Monitoring
时间窗: Fifteen days
Fifteen days of sensor wear with the Cascade CGM Smart Device App
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Cascade Continuous Glucose Monitor (CGM) 15-Day US Performance AssessmentContinuous Glucose MonitoringNCT04397965WaveForm Technologies Inc.10
已完成
不适用
Periodic Use of Continuous Glucose Monitoring With Personalized Diet Interventions Using AI Camera Among Non-insulin Treated Type 2 DiabetesType 2 DiabetesNCT06594055Kangbuk Samsung Hospital120
撤回
不适用
Temporary Use of a Continuous Glucose Monitoring System as an Adjunct to Lifestyle Medicine EducationBlood Glucose ProfileNCT04306848Ohio University
已完成
不适用
CGM Use in Children With Type 2 DiabetesHyperglycemia Due to Type 2 Diabetes MellitusType 2 DiabetesNCT04721158Johns Hopkins University41
已完成
1 期
Evaluation of Continuous Glucose Monitoring in Participants With Type 2 Diabetes Mellitus (MK-0000-258 AM2)Type 2 Diabetes MellitusNCT01537120Merck Sharp & Dohme LLC25